Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration. (2nd January 2016)

• Record Type: Journal Article
• Authors: Hirani, Anjali; Grover, Aditya; Lee, Yong W.; Pathak, Yashwant; Sutariya, Vijaykumar
• Is Part Of: Pharmaceutical development and technology. Volume 21:Number 1(2016)
• Page Start: 61
• Page End: 67
• Publication Date: 2016-01-02
• Subjects: Age-related macular degeneration -- PLGA nanoparticles -- triamcinolone acetonide -- thermoreversible gel -- VEGF; Drug delivery systems -- Periodicals; Pharmaceutical technology -- Periodicals; Drugs -- Administration -- Research -- Periodicals; Drug Delivery Systems -- Periodicals; Pharmaceutical Preparations -- Periodicals; Technology, Pharmaceutical -- Periodicals; 615
• DOI: 10.3109/10837450.2014.965326
• Languages: English
• ISSNs: 1083-7450

Abstract

Abstract: Age-related macular degeneration (AMD) is one of the leading causes of blindness in the US affecting millions yearly. It is characterized by intraocular neovascularization, inflammation and retinal damage which can be ameliorated through intraocular injections of glucocorticoids. However, the complications that arise from repetitive injections as well as the difficulty posed by targeting the posterior segment of the eye make this interesting territory for the development of novel drug delivery systems (DDS). In the present study, we described the development of a DDS composed of triamcinolone acetonide-encapsulated PEGylated PLGA nanoparticles (NP) incorporated into PLGA–PEG–PLGA thermoreversible gel and its use against VEGF expression characteristic of AMD. We found that the NP with mean size of 208 ± 1.0 nm showed uniform size distribution and exhibited sustained release of the drug. We also demonstrated that the polymer can be injected as a solution and transition to a gel phase based on the biological temperature of the eye. Additionally, the proposed DDS was non-cytotoxic to ARPE-19 cells and significantly reduced VEGF expression by 43.5 ± 3.9% as compared to a 1.53 ± 11.1% reduction with triamcinolone. These results suggest the proposed DDS will contribute to the development of novel therapeutic strategies for AMD.